Abstract We examined estrogen receptor (ER) mRNA expression and molecular subtypes in stage I-III breast cancers that are progesterone receptor (PR) positive but ER and HER2 negative by immunohistochemistry (IHC) or fluorescent in situ hybridization. The ER, PR, and HER2 status was determined by IHC as part of routine clinical assessment (N = 501). Gene expression profiling was done with the Affymetrix U133A gene chip. We compared expressions of ESR1 and MKI67 mRNA, distribution of molecular subtypes by the PAM50 classifier, the sensitivity to endocrine therapy index, and the DLDA30 chemotherapy response predictor signature among ER/PR-positive (n = 223), ER-positive/ PR-negative (n = 73), ER-negative/PR-positive (n = 20), and triple-negative (n = 185) cancers. All patients received neoadjuvant chemotherapy with an anthracycline and taxane and had adjuvant endocrine therapy only if ER or PR [ 10 % positive. ESR1 expression was high in 25 % of ER-negative/ PR-positive, in 79 % of ER-positive/PR-negative, in 96 % of ER/PR-positive, and in 12 % of triple-negative cancers by IHC. The average MKI67 expression was significantly higher in the ER-negative/PR-positive and triple-negative cohorts. Among the ER-negative/PR-positive patients, 15 % were luminal A, 5 % were Luminal B, and 65 % were basal like. The relapse-free survival rate of ER-negative/PR-positive patients was equivalent to ER-positive cancers and better than the triple-negative cohort. Only 20-25 % of the ER-negative/ PR-positive tumors show molecular features of ER-positive cancers. In this rare subset of patients (i) a second RNA-based assessment may help identifying the minority of ESR1 mRNA-positive, luminal-type cancers and (ii) the safest clinical approach may be to consider both adjuvant endocrine and chemotherapy.
Introduction
Estrogen (ER) and progesterone receptor (PR) are routinely assessed in all primary breast cancers by immunohistochemistry (IHC) [1] and adjuvant endocrine therapy is recommended if either of these receptors is positive (i.e., [1 % by IHC) [2] [3] [4] . The expression of PR is activated by ERa via an estrogen-responsive element-containing gene promoter. Therefore, it has been proposed that PR expression indicates the presence of functional ERa [5] and loss of PR expression potentially defines a subpopulation of patients with inferior benefit from tamoxifen compared to PR receptor persisted cancers [6] . In this model, the existence of ER-negative/PR-positive cancers represents an enigma. It has even been suggested that the majority of ERnegative but PR-positive cancers may represent false-negative IHC results for ER [7] . After reevaluation of the tumor slides and control tissues, most cases of ER-negative/PR-positive cases changed their original phenotype [7] . Further, Hefti et al. [8] also reported that ER-negative/ PR-positive cases showed no significant reproducibility by integrated gene expression microarray and clinico-pathological data.
The prognostic value of PR expression independent of any endocrine therapy and its interaction with benefit from endocrine therapy in ER-positive cancers has been documented by several studies. In ER-positive cancers, patients with PR-positive disease have lower risks of recurrence and mortality compared to PR-negative cancers both with and without adjuvant endocrine therapy [9] . Prat et al. [10] reported that PR expression adds to the prognostic value of luminal A classification and can further sub-stratify patients among luminal cancers. Viale et al. [11] also showed that PR expression predicts for adjuvant chemotherapy benefit among pre-and peri-menopausal but not post-menopausal patients with ER-positive cancers. The predictive and prognostic value of PR expression in ERnegative cancers is much less understood, mostly because of the rarity of this disease subset.
Approximately 3 % of all breast cancers are ER negative and PR positive [12] . Some data suggest that cancers may not significantly benefit from adjuvant endocrine therapy [9] . In 2010, joint guidelines by the American Society of Clinical Oncology (ASCO) and the American College of Pathologists recommended that hormone receptor (HR) status should be considered positive if 1 % or more tumor cells demonstrate positive nuclear staining of either ER or PR with an IHC assay [1] . Historically, many investigators and clinicians considered 10 % or greater IHC staining as the threshold for defining HRpositive status and, therefore, eligibility for endocrine therapy. We have previously showed that the majority of ER borderline, 1-9 % IHC positive, cases had molecular features similar to ER-negative cancers [13] .
In the current study, we examined ESR1 mRNA expression and molecular subtype distribution among ER-negative but PR-positive cancers and assessed hormone and chemotherapy sensitivity markers in these cancers [14, 15] . The purpose of these analyses was to determine whether ER-negative/PR-positive cancers show the same global gene expression patterns and molecular subtypes as ER-positive cancers do or if they are more similar to ER-negative cancers.
Patients and methods
Five hundred and one patients were included in this study who participated in a prospective Institutional Review Board-approved biomarker discovery study at MD Anderson Cancer Center in Houston, TX and signed informed consent for molecular analysis of their pretreatment cancer biopsy and had routine marker and gene expression data available. The ER, PR, and HER2 status was assessed on diagnostic core needle biopsies in the routine pathology laboratory. Clinical ER status was determined by IHC using the ERalfa antibody 6F11 (Novocastra/Vector Laboratories, Burlingame, CA) and PR status was determined by using the antibody 1A6 (Novacastra Laboratories Ltd., Burlingame, CA). The cut-off for ER or PR positivity for this analysis was [1 % tumor cells with nuclear staining. HER2 status had been assessed either by fluorescence in situ hybridization or by IHC (Dako North America, Inc., Carpinteria, CA, USA). HER2 positivity had been defined as either HER2 gene amplification if immunohistochemical score was 2? or an immunohistochemical score of 3?. Two hundred and twenty-three patients were ER and PR positive, 73 were ER positive but PR negative, 20 were ER negative but PR positive, and 185 were ER and PR negative. All patients received neoadjuvant chemotherapy containing a taxane-and anthracyclinebased regimen, and patients with ER-or PR-positive tumors defined as C10 % staining also received adjuvant endocrine therapy.
Gene expression profiling with Affymetrix U133 gene chips were performed on fine-needle aspirations obtained before any therapy and independent of the diagnostic coreneedle biopsy used for routine ER, PR, and HER2 determination. Gene expression data are available under GEO (Gene Expression Omnibus) accession number GSE 25066 and methods were described in a previous publication [16] . Expression data were normalized with the MAS5 algorithm, mean centered to 600 and log2 transformed. Probe set 205225_at was used as the measure of ESR1 mRNA expression, and a log2-transformed expression value of C10.18 was considered as ER positive by mRNA based on of a threshold established and validated in previous publications [13, 17, 18] . We also assessed PR mRNA expression by probe set 208305_at and Ki67 (MKI67) expression by probe set 212021_s_at. An ER metagene was calculated as the average log2 transformed expression values of ESR1, PR, BCL2, and SCUBE2 as measure of endocrine sensitivity (based on OncotypeDX ER score). The PAM50 classifier, the sensitivity to endocrine therapy (SET) index, and the DLDA30 chemotherapy response predictor signature were also applied to the data as previously described [14] [15] [16] 19] . The Wilcoxon test was used to determine statistical significance of gene expression differences between IHC subsets. We also plotted survival curves with the log-rank test by ER and PR status based on IHC. Statistical analyses were performed using the BRB-ArrayTools v 4.1.0 (http://linus. nci.nih.gov/BRB-ArrayTools.html) and the R software v 2.7.2 (http://www.r-project.org). Two-sided p values \0.05 were considered statistically significant.
Results
Patients characteristics are shown in Table 1 (Table 2 ). Among the ER-negative/PR-positive patients, 15 % were luminal A, 5 % were Luminal B, and 65 % were basal like; among the ER-positive/PR-negative patients, 59 % were luminal type ( Table 2 ). An additional 22 patients who were IHC ER/PR negative (12 % of ER/ PR-negative cases) were positive by ESR1 mRNA gene expression and may be considered as false-negative IHC results ( Table 2 ). The sensitivity to endocrine therapy (SET) index assigned low sensitivity to 90 % of the ERnegative/PR-positive cancers ( Table 2 ). The chemotherapy sensitivity gene score, DLDA30, predicted high chemotherapy sensitivity for 60 % of the ER-negative/PR-positive patients and for 21 % of ER-positive/PR-negative patients (Table 2 ). Only 5 % (12/233) of the ER/PR-positive patients were assigned to the high chemotherapy sensitivity group. Figure 1 shows the relationship between ER/PR protein expression and ESR1, PR, and MKI67 mRNA gene expression and the ER metagene. The associations between IHC ER/PR subtypes and the mRNA gene expression level (ESR1-, PR-, and ER-related genes) were similar and consistent, indicating that they were highly correlated each other. The majority of the ER-negative/PR-positive patients (75 %) showed low ESR1 mRNA, low PR, and low ER metagene expression, and were assigned to ERnegative status by these metrics. In contrast, the majority of ER-positive/PR-negative cases showed high ESR1 and ER metagene expression that were consistent with ER-positive status. The average MKI67 expression was also significantly higher in the ER-negative/PR-positive and ER/PRnegative cancers compared to other subtypes (Fig. 1) . Among the ER negative/PR positive, ER positive/PR negative, ER/PR positive, and ER/PR negative, 40 % (8/20), 16 % (12/73), 8 % (18/223), and 32 % (60/185) achieved pathological complete response that was defined as the absence of any residual invasive cancer in the breast and the absence of any metastatic cells in the regional lymph nodes after neoadjuvant chemotherapy. The relapsefree survival rate of ER-negative/PR-positive patients who received chemotherapy (and nine of them received additional adjuvant endocrine therapy) was equivalent to ER/ PR-positive or ER-positive/PR-negative cases that received both endocrine and chemotherapy, and significantly better than the relapse-free survival of ER/PR-negative cancers (Fig. 2) .
Discussions
ER-negative/PR-positive breast cancers are rare; this study and previous studies indicate that approximately 3-4 % if all breast cancers fall into this category [12] . Since it represents a rare receptor subtype, it is unlikely that a prospective clinical trial would ever be conducted to c ER-related genes refers to the average expression of 4 probe sets that are highly coexpressed with ESR1 [25] . d Expression distribution of MKI67 mRNA. P values were calculated with the Wilcoxon test define the optimal adjuvant treatment strategy for this disease. ER-negative/PR-positive status may arise from testing artifacts, including false-positive IHC results in a truly HR-negative tumor [20] or erroneously ER-negative results in a truly ER-positive tumor. It may also indicate the presence of tumor heterogeneity as a small PR positive subpopulation of cells within a larger both ER/PR-negative tumor. In our study, IHC ER/PR status defined by the routine analysis has been done on a fixed core needle biopsy, whereas the molecular profiling has been realized on another frozen samples by fine-needle aspirations. Discordance form the distinct methods of the sampling and the possibilities of false-positive or -negative results may be inevitable [21] . mRNA-based methods to assess hormone receptor status may help resolve some of these uncertainties [22] . We assessed gene expression profiling data in 501 primary breast cancer to find out how often ERnegative/PR-positive patients by IHC showed molecular features of ER-positive disease.
The minority (25 %) of ER-negative/PR-positive tumors and the majority (79 %) of ER-positive/PR-negative tumors showed ER-positive status by ESR1 mRNA gene expression data and had high expression of ER-related genes. Five of twenty patients with ER-negative/PR-positive cancers by IHC were ER positive by ESR1 mRNA and ER metagene expression. Four of these five cancers were also classified as luminal subtypes by the PAM50 classifier and, therefore, likely represent false-negative ER IHC results. On the other hand, 15 of the 20 ER negative/PR positive cancers showed low ESR1 mRNA and ER metagene expression and all of these cancers were classified as non-luminal subtypes by a PAM50. This suggests that the majority of ER-negative but PR-positive cancers may not be endocrine sensitive. However, the mRNA measurements represent bulk expression results for heterogeneous tissue. It is possible that small truly PR-positive and endocrinesensitive subpopulation of cells may exist within a larger ER/PR-negative tumor and signal from these cells is not apparent in the global expression data from the whole tissue [11, 23, 24] .
In these series, twenty ER-negative/PR-positive patients who received chemotherapy (and about half of them received additional adjuvant hormone therapy) have equivalent prognosis to ER/PR positive or ER positive/PR negative that received both chemo and hormone therapies. Overall, the expected benefit from hormone therapy is small in ER-negative/PR-positive tumors because majority of these tumors tend to be ER negative by ESR1 mRNA (75 %), show low predicted hormone sensitivity by the SET gene signature (90 %), and are predominantly nonluminal class (85 %). On the other hand, 60 % of the ERnegative/PR-positive cancers were predicted to have high chemotherapy sensitivity by the DLDA30 predictor.
This study has limitations. The number of ER-negative/ PR-positive patients in this analysis is low. No prior study examined the molecular features of this rare disease subset In summary, only 20-25 % of the ER-negative/PR-positive tumors show molecular features of ER-positive cancers (i.e., high ER mRNA expression and luminal molecular class). These cancers also have higher proliferation rate than ER-positive cancers, higher predicted chemotherapy sensitivity, and lower predicted hormone sensitivity. We concluded that in this rare subset of patients (i) a second RNAbased assessment may help identifying the minority of ESR1 mRNA-positive, luminal-type cancers and (ii) due to the substantial uncertainty about endocrine sensitivity and high chemotherapy sensitivity in this IHC ER-negative/PRpositive cancer population, the safest clinical approach may be to consider both adjuvant endocrine and chemotherapy.
